Life Science Connect Blog

31. FDA News Roundup: Valeant, Pfizer, Boehringer Ingelheim, And More 5/29/2015

    What FDA decisions have you missed recently?

32. Love Me, Love Me Not — The Life Science Industry's Paradox 5/28/2015

    Cold-hearted logic dominates the quest for shareholder value, even as industry insiders complain that “nobody loves us.” What better example of the conundrum exists than the current commentary about Gilead and its wonder drugs for Hep C?

33. FDA News Roundup: Baxter, Celgene, Agios, And More 5/22/2015

    What FDA decisions have you missed recently?

34. FDA News Roundup: Vertex, Merck KGaA , Bayer, And More 5/15/2015

    What recent FDA decisions have you missed lately?

35. What's The Hang Up With Drug Cost Transparency? Blame It On “Innovation” 5/12/2015

    A few months ago, a study came out examining the escalating costs of cancer treatments, which, no secret here, have left payers, patients, and lawmakers increasingly agitated and demanding answers.

36. FDA News Roundup: Biogen Idec, GSK, Roche, And More 5/8/2015

    What regulatory decisions have you missed lately?

37. Breakthrough Therapy Designation: Worth The Development Time Crunch, Experts Say 5/4/2015

    When I hear the words “Breakthrough Therapy Designation” (BTD), I immediately picture a gold-embossed certificate with a blue ribbon. After all, the designation is reserved for those candidates that, early on in clinical studies, promise more extraordinary benefits than the current standard-of-care treatments for a disease. Judging from the recent buzz I’ve noticed in the industry, the increasing number of treatments boasting this designation is in no way eliminating its prestige.

38. FDA News Roundup: Kythera Bio, Boehringer Ingelheim, GW Pharma, And More 5/1/2015

    What recent FDA decisions did you miss?

39. Clinical Trial Data Transparency: The Dangers Of “Putting It In Layman's Terms” 4/27/2015

    It’s been an exciting and tumultuous few months for ALS patients and the small biotech Genervon. The lengthening saga among the company, the FDA, and the army of eager, treatment-seeking ALS patients culminated recently in an order from the FDA that Genervon publicly release all data from the Phase 2 trial of its ALS candidate GM604. In a statement released early this week, Genervon said it had submitted all required data to the FDA for review. 

40. FDA News Roundup: AstraZeneca, Pfizer, AbbVie, Actavis, And More 4/24/2015

    What FDA decisions did you miss this week?